Mycophenolate mofetil: Emerging as a potential human teratogen

Canadian Family Physician

Volumn 54, Issue 8, 2008, Pages 1112-1113

  Koren, Gideon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TERATOGENIC AGENT;

ANIMAL EXPERIMENT; CLEFT LIP; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DIAPHRAGM HERNIA; DRUG MECHANISM; DRUG SUBSTITUTION; GENETIC RISK; GRAFT REJECTION; HYPOPLASIA; INCIDENCE; KIDNEY FAILURE; MICROGNATHIA; MICROTIA; ORGAN TRANSPLANTATION; PHENOTYPE; PREGNANCY; RISK FACTOR; SHORT SURVEY; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY, ANIMAL; PREGNANCY, HIGH-RISK; PRENATAL CARE; RABBITS; RATS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TERATOGENS; TRANSPLANTATION IMMUNOLOGY;

EID: 49649105014     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Sollinger HW; US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60(3):225-32.
2. CellCept (mycophenolate mofetil) [package insert]. Nutley, NJ: Roche Laboratories Inc; 2005.
3. Armenti VT, Moritz MJ, Cardonick EH, Davison JM. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs 2002;62(16):2361-75.
4. Mastrobattista JM, Katz AR. Pregnancy after organ transplant. Obstet Gynecol Clin N Am 2004;31(2):415-28.
5. Tendron A, Gouyon JB, Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 2002;17(2):121-30.
6. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006;82(12):1698-702.
7. Pérgola PE, Kancharla A, Riley DJ. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 2001;71(7):994-7.
8. Perez-Aytes A, Ledo A, Boso V, Sáenz P, Roma E, Poveda JL, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008;146A(1):1-7.
9. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 2004;103(5 Pt 2):1091-4.
10. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71(8):1051-5.